Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Ipsen
Woman and Man Max 99 years
Ipsen Innovation
Update Il y a 4 ans
The aim of the study is to assess the efficacy and safety of intra - detrusor injections of Dysport versus placebo in subjects suffering from neurogenic detrusor overactivity following spinal cord injury or multiple sclerosis
The primary study objective is to assess the efficacy of a single dose of Dysport (750 U) compared to placebo for the improvement in the daily incontinence episode frequency (IEF) for each administrat...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Beaufour Ipsen Pharma S.A.S
Update Il y a 4 ans
A phase II, multicentre, multinational, prospective, randomised, double-blind, placebo controlled study assessing the efficacy and safety of a single application of three doses of Dysport in patients with upper back myofascial pain syndrome (MPS)
To compare the efficacy of a single application of Dysport (100, 300 or 500 units) injected into 3 to 6 trigger points (TPs) located in the upper back musculature of adults with (MPS) with placebo
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Beaufour Ipsen Pharma
Update Il y a 4 ans
EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIA A 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study
To demonstrate an improvement in skeletal muscle energetics and particularly in mitochondrial oxidative phosphorylation.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Beaufour Ipsen Pharma
Update Il y a 4 ans
A Phase III, Prospective, Multicentre, Randomised, Open, Parallel Group Comparison of Lanreotide Autogel (90 and 120mg) Administered by Deep Subcutaneous Injection Every Four Weeks, with Sandostatin LAR Depot (20 and 30mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated with Carcinoid Syndrome
To evaluate the efficacy of lanreotide Autogel (90 and 120 mg), compared with Sandostatin LAR Depot (20 and 30 mg), in terms of the frequency of target symptom episodes, assessed by the change ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Ipsen Innovation
Update Il y a 4 ans
This study will aim to assess the safety and how effective the next generation of BTX-AHAC (BTX-A-HAC NG) with an injectable liquid formulation is for improving the appearance of lines (wrinkles) between the eyebrows (glabellar area) after repeated treatment
The objective of the study is to assess short-term efficacy and safety of a single treatment of BTX-A-HAC NG over placebo for the improvement in the appearance of glabellar lines and to assess the lon...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Ipsen Pharma
Update Il y a 4 ans
A study with tasquinimod, treating patients with hepatocellular, ovarian, renal cell and gastric cancers
To determine the clinical activity of tasquinimod in advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas in patients who progressed after standard therapies Clinical acti...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Ipsen Pharma
Update Il y a 4 ans
Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome
Part A The primary study objective is to assess the efficacy of repeated s.c. injections at different doses of BIM 23A760 on patient’s overall satisfaction in terms of symptom relief (diarrhoea and/...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Ipsen
Update Il y a 5 ans
Étude CLARINET FORTE : étude de phase 2, évaluant l’efficacité et la tolérance du lanreotide autogel® 120 mg administré tous les 14 jours, chez des patients ayant un cancer du pancréas ou une tumeur neuroendocrine du tube digestif, non résécable localement avancé ou métastatique en progression après un traitement standard par lanreotide autogel® 120 mg.
Les tumeurs neuroendocrines du pancréas ou de l’intestin moyen sont des tumeurs rares qui ont une progression lente. Les thérapies disponibles pour traités ces tumeurs sont limitées, d’où le besoin de...
Country
France
organs
Pancréas
,
Tumeurs endocrines digestives
Specialty
Hormonothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Ipsen Ltd
Update Il y a 4 ans
A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia
To evaluate the efficacy and safety of intramuscular administration of Dysport (500 units) compared to placebo for the treatment of cervical dystonia
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6